短疗程AL-335联合奥达拉韦含或不含西美瑞韦治疗无肝硬化HCV GT1或3感染患者
这项开放标签IIa期研究评估了AL-335联合奥达拉韦含或不含西美瑞韦的6-12周口服方案,在112例初治、无肝硬化的HCV GT1或3感染患者中的安全性、药代动力学和疗效。GT1患者接受三药方案6-8周均达到100%的SVR12/24,而GT1患者接受两药方案或GT3患者接受三药方案的SVR12/24均低于90%。
要点
- GT1初治无肝硬化患者接受三药方案6-8周,SVR12/24达100%。
- GT1两药方案及GT3三药方案SVR12/24均不足90%。
- 病毒学失败多与NS5A和/或NS5B耐药相关替换出现有关。
核心结论
- 在初治无肝硬化患者中,AL-335+奥达拉韦+西美瑞韦6-8周对HCV GT1总体安全且高效,但GT1两药方案和GT3三药方案疗效不足。
研究设计与样本
- 开放标签IIa期研究,共纳入112例初治、无肝硬化的HCV GT1或GT3感染患者,评估多种6-12周口服方案。
- 方案包括AL-335 400-800 mg每日一次+奥达拉韦50 mg每日一次或隔日一次±西美瑞韦75-150 mg每日一次。
- 评估安全性/药代动力学参数、HCV-RNA及测序数据。
- 后续研究队列的治疗方案根据新出现的数据进行调整。
主要发现
- 发生3例严重治疗中出现的不良事件,其中1例(莫氏I型二度房室传导阻滞[文氏现象])可能与奥达拉韦高暴露有关并导致研究药物提前终止。
- GT1患者接受三药方案6-8周,SVR12/24为100%。
- GT1患者接受两药方案或GT3患者接受三药方案,无论治疗8周还是12周,SVR12/24均低于90%。
- 多数病毒学失败患者出现通常持续存在的NS5A和/或短暂出现的NS5B耐药相关替换。
- 阐明了三种药物的药代动力学特征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This open-label, phase IIa study assessed the safety, pharmacokinetics, and efficacy of direct-acting antiviral agent (DAA) regimens in patients with chronic hepatitis C virus (HCV) infection. Multiple 6-12-week oral regimens of 400-800 mg once daily (QD) AL-335 + 50 mg QD/every other day odalasvir ± 75-150 mg QD simeprevir were evaluated in treatment-naïve, HCV genotype (GT)1/3-infected patients without cirrhosis. Safety/pharmacokinetic parameters, HCV-RNA, and sequencing data were assessed. Treatment regimens for later study cohorts were adjusted based on emerging data. In total, 112 patients were enrolled. Three serious treatment-emergent adverse events occurred, one of which (a Mobitz type 1 second-degree atrioventricular block [Wenckebach]) was possibly related to high odalasvir exposure and resulted in premature discontinuation of study drugs. No other clinically significant safety findings were identified. GT1-infected patients receiving 3-DAA for 6-8 weeks achieved 100% sustained virologic response 12 weeks and 24 weeks after the end of treatment (sustained virologic response [SVR12/24]). GT1-infected patients receiving 2-DAA or GT3-infected patients receiving 3-DAA had SVR12/24 less than 90%, whether treated for 8 weeks or 12 weeks. Virologic failure was associated with the emergence of generally persistent NS5A and/or transient NS5B resistance-associated substitutions in most patients. Pharmacokinetic characteristics of the three drugs were also elucidated. Conclusions: In treatment-naïve subjects without cirrhosis, AL-335 + odalasvir + simeprevir for 6-8 weeks was generally safe and highly efficacious against HCV GT1. However, inadequate efficacy was observed for the 2-DAA regimen in GT1-infected subjects and the 3-DAA regimen in GT3-infected subjects.
引用
- Gane EJ, Stedman CA, Schwabe C, et al. Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis. Hepatology. 2018. PMID: 30070722. doi:10.1002/hep.30126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。